Micronoma in the News

The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early detection of lung cancer. The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma.1 The OncobiotaLUNG assay is...

Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a...

The FDA has granted Breakthrough Device status to Micronoma’s OncobiotaLUNG microbiome-driven blood assay for early lung cancer detection. Lung cancer is currently diagnosed though computed tomography scanning in which, when an indeterminate lung nodule is found, the...

Forbes has named Micronoma CAO and Co-founder Gregory Sepich-Poore one of its 30 Under 30 in Healthcare for 2023.  Read more at Forbes.  

A flurry of microbiome research over the past two decades has led to many insights about the link between the microbes and health, but now the race to the clinic is on. Over the past two decades scientists have been working steadily to unravel the complex interplay of...

Fungal communities (mycobiota) constitute a subset of the human microbiome that can trigger an immune response, but little is known about their presence or functional role in human cancers. Two independent studies published in the journal Cell, report converging...

An international team of scientists, co-led by researchers at the University of California San Diego School of Medicine, has created the first pan-cancer mycobiome atlas — a survey of 35 types of cancer and their associated fungi. The findings are published September...

Fungal DNA is present in various types of cancer, according to two studies published yesterday (September 29) in Cell. The findings add support to a hypothesized link between fungi and certain cancers, although researchers emphasize that there isn’t yet evidence for a...

New research is revealing that cancer is rife with bacteria and fungi - a rich ecosystem that scientists call the tumor microbiome. Read more at The New York Times

By Deborah Borfitz  September 22, 2022 | Emerging approaches to the early detection of cancer, based on metabolic profiling and microbiome- and exosome-driven liquid biopsies, were highlighted during the recent Next Generation Dx Summit held in Washington, D.C....

When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...

The revelation that our commensal bacteria play important roles in health and disease has turned the microbiome into one of the most active frontiers of biomedicine. Yet our efforts to turn our “inner bugs” into drugs have long been limited to investigational fecal...

As a postdoc at the Broad Institute of MIT and Harvard in 2008, cancer biologist Ravid Straussman worked on a collaborative effort to screen normal cells for their influence on cancer cells’ responses to various anticancer therapies. The project turned up hundreds of...

With its Oncobiota platform, Micronoma is pioneering the analysis of the cancer microbiome for early cancer detection and creating tools for personalized cancer treatment. Read More

NEW YORK – Microbial cancer detection firm Micronoma said Tuesday that it is collaborating with... Read Article

After controlling for high levels of bacterial contamination in their lab and reagents, researchers detect microbial genetic material in plasma samples from healthy people and cancer patients. Read the full article in The Scientist

Micronoma, a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round. Read full story.

Read the article at CIO Applications

Micronoma’s microbiome platform is breaking into its next phase with validation from the U.S. Food and Drug Administration. Last month, the San Diego-based company announced that the FDA has given its OncobiotaLUNG assay Breakthrough Device Designation. The...

The FDA has granted breakthrough device designation to the novel, microbiome-driven, liquid biopsy assay OncobiotaLUNG for the detection of lung carcinomas, according to a press release from developer Micronoma.1 The assay is one of the first blood microbiome­–driven...

The FDA has granted the OncobiotaLUNG assay a breakthrough device designation for the early detection of lung cancer. The FDA has provided the OncobiotaLUNG assay a breakthrough device designation, according to the device maker, Micronoma.1 The OncobiotaLUNG assay is...

Micronoma, the first biotech company offering early cancer detection with a microbiome-driven liquid biopsy platform, announced today that its OncobiotaLUNG assay received the Breakthrough Device Designation from the Food and Drug Administration (FDA). As a...

We’ll start with the acquisition: This week, daily e-newsletter Morning Brew announced that it had acquired One Future, a digital media startup, with the hopes of tapping a larger Gen Z audience. The companies declined to disclose terms of the deal. Our Future...

Forbes has named Micronoma CAO and Co-founder Gregory Sepich-Poore one of its 30 Under 30 in Healthcare for 2023.  Read more at Forbes.  

A flurry of microbiome research over the past two decades has led to many insights about the link between the microbes and health, but now the race to the clinic is on. Over the past two decades scientists have been working steadily to unravel the complex interplay of...

Experts say fungi can be found in a variety of places in the human body as well as in cancer tumors. Researchers say the microorganisms may be useful in developing new diagnostic tools and treatments. They say fungi may be able to develop biomarkers to detect cancer...

An international team of scientists, co-led by researchers at the University of California San Diego School of Medicine, has created the first pan-cancer mycobiome atlas — a survey of 35 types of cancer and their associated fungi. The findings are published September...

Fungal DNA is present in various types of cancer, according to two studies published yesterday (September 29) in Cell. The findings add support to a hypothesized link between fungi and certain cancers, although researchers emphasize that there isn’t yet evidence for a...

A research team led by the University of California San Diego and the Weizmann Institute of Science in Israel has created an atlas of fungi linked to a range of 35 different cancers for the first time. As reported in the journal Cell, the researchers hope the new...

By Deborah Borfitz  September 22, 2022 | Emerging approaches to the early detection of cancer, based on metabolic profiling and microbiome- and exosome-driven liquid biopsies, were highlighted during the recent Next Generation Dx Summit held in Washington, D.C....

When scientists began mapping of the human genome, the discoveries in our DNA unleashed an era of biology that advanced breakthroughs in diagnostics and biomedicine beyond what was imaginable when the work began. Today, with DNA sequencers readily available in many...

The health category of Fast Company’s World Changing Ideas Awards honors medical innovations that save lives, extend longevity, or increase access to care. See the finalists and honorable mentions below, and read about the winner, the pill that could make routine...

As a postdoc at the Broad Institute of MIT and Harvard in 2008, cancer biologist Ravid Straussman worked on a collaborative effort to screen normal cells for their influence on cancer cells’ responses to various anticancer therapies. The project turned up hundreds of...

With its Oncobiota platform, Micronoma is pioneering the analysis of the cancer microbiome for early cancer detection and creating tools for personalized cancer treatment. Read More

Interview with Sandrine Miller-Montgomery, Micronoma, Inc. What are your suggestions to encourage more young women to pursue careers in tech? There are so many facets to working in tech that it is worth considering regardless of being scientific minded or not...the...

After controlling for high levels of bacterial contamination in their lab and reagents, researchers detect microbial genetic material in plasma samples from healthy people and cancer patients. Read the full article in The Scientist

Micronoma, a San Diego, Calif.-based cancer detection biotech company that utilizes signals from the tumor-related microbiome to diagnose cancer at an early stage with liquid biopsy technology, closed a $3.5m convertible debt financing round. Read full story.

Microbiome-based diagnostics and biomarkers: Changing the paradigm in microbiology and medicine. Read how Micronoma fits in this emerging landscape. Read Article